Cannabis Delivery of the Future Corporate Presentation JANUARY 2019
Forward Looking Statements Except for the historical information contained herein, the matters discussed in this presentation are forward looking statements within the meaning of the federal securities laws. Important factors could cause our actual results to differ materially from those contained in the forward looking statements including our growth strategies, our ability to successfully and economically commercialize our technology, anticipated trends in our business‚ our liquidity and ability to finance our development activities‚ market conditions in the industry‚ our ability to make and integrate acquisitions, the impact of governmental regulation and other risks more fully described in the company’s filings with the Securities and Exchange Commission. Forward looking statements are typically identified by use of terms such as “may,” “will,” “expect,” “anticipate,” “estimate” and similar words, although some forward looking statements may be expressed differently. All forward looking statements contained in this release, including any forecasts and estimates, are based on management’s outlook only as of the date of this release, and we undertake no obligation to update or revise these forward looking statements, whether as a result of subsequent developments or otherwise. 2 CORPORATE PRESENTATION / JANUARY 2019
GCANRx is a biopharmaceutical company focused on the development and commercialization of innovative cannabinoid delivery systems. GCANRx leverages its patented technology platform, which has been successfully used in other drug delivery applications, for the benefit of cannabis patients and consumers. 3 3 CORPORATE PRESENTATION / JANUARY 2019 CORPORATE PRESENTATION / JANUARY 2019
Cannabis use is growing exponentially, projected to surpass $32B in 2022. Legal Cannabis Spending (In Billions) $3.1 $2.4 $5.5 $4.5 $23.4 $1.5 $20.9 $1.0 $3.6 $2.7 $0.6 $17.8 $0.4 $14.4 $1.3 $0.6 $11.0 $8.5 Canada United States Rest of World Arcview Market Research/BDS Analytics 4 CORPORATE PRESENTATION / JANUARY 2019
However, current cannabis delivery systems are severely lacking. Inefficient Absorption Inaccurate Dosing Unhealthy Side Effects Inhalation: Bioavailability following the Inaccurate/Unpredictable Dosing: Cannabis Smoke: Similar to smoking tobacco, these include smoking route was reported as 2−56% , due Health professionals are wary about increased risks of exposure to ammonia ( 20x tobacco), hydrogen in part to intra- and inter-subject variability being able to provide accurate cyanide ( 5x tobacco), nitrogen oxides, and polycyclic aromatic in smoking dynamics. dosing. hydrocarbons (PAHs). Cannabis smoke contains thousands of organic and inorganic chemical compounds. This tar is chemically similar to Ingestion: Average bioavailability is 4-12% . According to a study in the June that found in tobacco smoke or cigars. Over fifty known carcinogens Less than 1% of cannabinoids actually reach 23/30 issue of JAMA, 83% of have been identified in cannabis smoke. These include nitrosamines, target receptors. This leads to increased cannabis products tested were reactive aldehydes, and polycylic hydrocarbons, including dosing to achieve desired effect, and found to have over or undervalued benz[a]pyrene. Marijuana smoke was listed as a cancer agent in inefficient consumer spending. the amount of Cannabinoids found in California in 2009. Increased risk to microorganisms from improper the product. processing including salmonella, mold, and known toxic and carcinogenic fungi. Ingestible products do not have as many side effects as smoking but have a much longer onset time and lower bioavailability due to first pass metabolism and GI degradation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC268951 8/ 5 CORPORATE PRESENTATION / JANUARY 2019
GCANRx’s Eluting Patch Platform (EPP) Our eluting patch platform (EPP) is an orally dissolving transmucosal thin film. Its multilayer system enables multiple cannabinoids and different dosages to be loaded onto the same patch, and delivered in pre-set intervals. • Easy-to-use (fully dissolvable) • No side effects • High bioavailability • Can control the absorption rate • Can load multiple compounds and dosages 6 CORPORATE PRESENTATION / JANUARY 2019 CORPORATE PRESENTATION / JANUARY 2019
GCANRx’s technology enables quicker desired effects with a lower, and more accurate, standardized dosing. GCANRx’s delivery platform can be utilized to deliver cannabis actives directly into the body without the harmful side effects of smoking or vaping , and with quicker onset and greater bioavailability than ingestibles. 7 CORPORATE PRESENTATION / JANUARY 2019 CORPORATE PRESENTATION / JANUARY 2019
Buccal Application: The patch is easy to use – just open and stick to the cheek. 8 CORPORATE PRESENTATION / JANUARY 2019
The patch has multiple layers and enables different dosages. Towards the oral cavity Towards buccal / gum tissue 9 CORPORATE PRESENTATION / JANUARY 2019
GCANRx’s patch has several advantages. Multi-layer and multi-purpose Rapid onset with slow, fast, and film that’s flexible and thin sustained release Needle-free intra-oral systemic drug High active material loading capacity delivery (50 mg) Bioadhesive and fully orally Easy, clean, and discrete administration dissolvable (use anytime, anywhere) • Lower Dosing: The transmembrane functionality enables needle-free, rapid • Controlled Release: Two or more layers of the eluting patch offers diverse drug absorption through transmucosal delivery, administering the medicine timing of drug administration. The inner film layer is attached to the directly into the blood while bypassing the digestive and hepatic systems. End membrane providing fast release and therapeutic onset, followed by the Rapid onset with slow, fast, and sustained results are higher bioavailability, and a therapeutic effect achieved with less outer film layers providing a slow and sustained release. release API. • Versatility: Each layer contains similar or different cannabinoids, which • Multi-Dosing: The mucoadhesive film is applied on the internal mouth, and is can be customized per the specific requirements of a consumer profile or made of multiple dosage form layers enabling loading of different dosages on patient subset. the same thin film patch. 10 CORPORATE PRESENTATION / JANUARY 2019
GCANRx's Eluting Patch Platform has been studied with support from the National Institutes of Health. Clinical pharmacokinetic studies were conducted and published in conjunction with Penn State School of Medicine. Results showed the eluting patch delivery as an novel delivery system was well tolerated and produced peak plasma levels in a similar range to those achieved by existing methods of administration. 11 CORPORATE PRESENTATION / JANUARY 2019
Our DEA-approved research and small scale manufacturing lab is located in New Brunswick, New Jersey. Biotechnology Development Center in New Brunswick, New Jersey 12 CORPORATE PRESENTATION / JANUARY 2019
Our IP assets are centered around cutting-edge delivery technologies. WO 2010/135053 A2 (IP from Pharmedica Ltd) • Dual and single layer dosage forms. • Issued US patent on April 28, 2015. US 62/737,153 • Oral dissolving film for rapid and sustained release and delivery of Cannabinoids. • Provisional filed on 9/27/2018. • Utility filing estimated completion is Q1 2019. 13 CORPORATE PRESENTATION / JANUARY 2019
GCANRx is focused on commercializing its technology in the global market through both medical and recreational uses. This will be done through partnerships with leading: Cannabis Licensed Consumer Pharmaceutical Companies Focused Producers/Processors Products Brands on Cannabinoids Therapies We partner with regional license holders and leverage their distribution channels to accelerate our market penetration. 14 CORPORATE PRESENTATION / JANUARY 2019
Recommend
More recommend
